vs
Side-by-side financial comparison of Cintas (CTAS) and TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA). Click either name above to swap in a different company.
TEVA PHARMACEUTICAL INDUSTRIES LTD is the larger business by last-quarter revenue ($4.7B vs $2.8B, roughly 1.7× Cintas). Cintas runs the higher net margin — 17.7% vs 10.2%, a 7.5% gap on every dollar of revenue. On growth, TEVA PHARMACEUTICAL INDUSTRIES LTD posted the faster year-over-year revenue change (11.4% vs 9.3%). TEVA PHARMACEUTICAL INDUSTRIES LTD produced more free cash flow last quarter ($1.0B vs $425.0M). Over the past eight quarters, TEVA PHARMACEUTICAL INDUSTRIES LTD's revenue compounded faster (11.1% CAGR vs 7.9%).
Cintas Corporation is an American corporation headquartered in Mason, Ohio, which provides a range of products and services to businesses including uniforms, mats, mops, cleaning and restroom supplies, first aid and safety products, fire extinguishers and testing, and safety courses. Cintas is a publicly held company traded on the Nasdaq Global Select Market under the symbol CTAS and is a component of the S&P 500 Index.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
CTAS vs TEVA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $4.7B |
| Net Profit | $495.3M | $481.0M |
| Gross Margin | 50.4% | 56.4% |
| Operating Margin | 23.4% | 6.4% |
| Net Margin | 17.7% | 10.2% |
| Revenue YoY | 9.3% | 11.4% |
| Net Profit YoY | 10.4% | 321.7% |
| EPS (diluted) | $1.21 | $0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $4.7B | ||
| Q3 25 | $2.7B | $4.5B | ||
| Q2 25 | $2.7B | $4.2B | ||
| Q1 25 | $2.6B | $3.9B | ||
| Q4 24 | $2.6B | $4.2B | ||
| Q3 24 | $2.5B | $4.3B | ||
| Q2 24 | $2.5B | $4.2B | ||
| Q1 24 | $2.4B | $3.8B |
| Q4 25 | $495.3M | $481.0M | ||
| Q3 25 | $491.1M | $433.0M | ||
| Q2 25 | $448.3M | $282.0M | ||
| Q1 25 | $463.5M | $214.0M | ||
| Q4 24 | $448.5M | $-217.0M | ||
| Q3 24 | $452.0M | $-437.0M | ||
| Q2 24 | $414.3M | $-846.0M | ||
| Q1 24 | $397.6M | $-139.0M |
| Q4 25 | 50.4% | 56.4% | ||
| Q3 25 | 50.3% | 51.4% | ||
| Q2 25 | 49.7% | 50.3% | ||
| Q1 25 | 50.6% | 48.2% | ||
| Q4 24 | 49.8% | 50.2% | ||
| Q3 24 | 50.1% | 49.6% | ||
| Q2 24 | — | 48.6% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | 23.4% | 6.4% | ||
| Q3 25 | 22.7% | 19.7% | ||
| Q2 25 | 22.4% | 10.9% | ||
| Q1 25 | 23.4% | 13.3% | ||
| Q4 24 | 23.1% | -0.7% | ||
| Q3 24 | 22.4% | -1.2% | ||
| Q2 24 | 22.2% | -0.1% | ||
| Q1 24 | 21.6% | -5.7% |
| Q4 25 | 17.7% | 10.2% | ||
| Q3 25 | 18.1% | 9.7% | ||
| Q2 25 | 16.8% | 6.8% | ||
| Q1 25 | 17.8% | 5.5% | ||
| Q4 24 | 17.5% | -5.1% | ||
| Q3 24 | 18.1% | -10.1% | ||
| Q2 24 | 16.8% | -20.3% | ||
| Q1 24 | 16.5% | -3.6% |
| Q4 25 | $1.21 | $0.42 | ||
| Q3 25 | $1.20 | $0.37 | ||
| Q2 25 | $1.08 | $0.24 | ||
| Q1 25 | $1.13 | $0.18 | ||
| Q4 24 | $1.09 | $-0.19 | ||
| Q3 24 | $1.10 | $-0.39 | ||
| Q2 24 | $4.00 | $-0.75 | ||
| Q1 24 | $3.84 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $200.8M | $3.6B |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $4.5B | $7.9B |
| Total Assets | $10.1B | $40.7B |
| Debt / EquityLower = less leverage | 0.54× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $200.8M | $3.6B | ||
| Q3 25 | $138.1M | $2.2B | ||
| Q2 25 | $264.0M | $2.2B | ||
| Q1 25 | $243.4M | $1.7B | ||
| Q4 24 | $122.4M | $3.3B | ||
| Q3 24 | $101.4M | $3.3B | ||
| Q2 24 | $342.0M | $2.3B | ||
| Q1 24 | $128.5M | $3.0B |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.0B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $2.5B | — |
| Q4 25 | $4.5B | $7.9B | ||
| Q3 25 | $4.8B | $7.3B | ||
| Q2 25 | $4.7B | $6.8B | ||
| Q1 25 | $4.6B | $6.3B | ||
| Q4 24 | $4.3B | $5.4B | ||
| Q3 24 | $4.0B | $6.1B | ||
| Q2 24 | $4.3B | $6.4B | ||
| Q1 24 | $4.2B | $7.3B |
| Q4 25 | $10.1B | $40.7B | ||
| Q3 25 | $9.8B | $39.9B | ||
| Q2 25 | $9.8B | $40.1B | ||
| Q1 25 | $9.6B | $38.4B | ||
| Q4 24 | $9.4B | $39.3B | ||
| Q3 24 | $9.1B | $41.8B | ||
| Q2 24 | $9.2B | $41.3B | ||
| Q1 24 | $9.0B | $42.8B |
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.44× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.50× | — | ||
| Q2 24 | 0.47× | — | ||
| Q1 24 | 0.58× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $531.2M | $1.2B |
| Free Cash FlowOCF − Capex | $425.0M | $1.0B |
| FCF MarginFCF / Revenue | 15.2% | 21.6% |
| Capex IntensityCapex / Revenue | 3.8% | 3.0% |
| Cash ConversionOCF / Net Profit | 1.07× | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | $1.8B | $1.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $531.2M | $1.2B | ||
| Q3 25 | $414.5M | $369.0M | ||
| Q2 25 | $635.7M | $227.0M | ||
| Q1 25 | $622.0M | $-105.0M | ||
| Q4 24 | $441.4M | $575.0M | ||
| Q3 24 | $466.7M | $693.0M | ||
| Q2 24 | $693.0M | $103.0M | ||
| Q1 24 | $657.1M | $-124.0M |
| Q4 25 | $425.0M | $1.0B | ||
| Q3 25 | $312.5M | $233.0M | ||
| Q2 25 | $521.1M | $131.0M | ||
| Q1 25 | $522.1M | $-232.0M | ||
| Q4 24 | $340.0M | $446.0M | ||
| Q3 24 | $373.8M | $545.0M | ||
| Q2 24 | $591.1M | $6.0M | ||
| Q1 24 | $550.1M | $-248.0M |
| Q4 25 | 15.2% | 21.6% | ||
| Q3 25 | 11.5% | 5.2% | ||
| Q2 25 | 19.5% | 3.1% | ||
| Q1 25 | 20.0% | -6.0% | ||
| Q4 24 | 13.3% | 10.5% | ||
| Q3 24 | 14.9% | 12.6% | ||
| Q2 24 | 23.9% | 0.1% | ||
| Q1 24 | 22.9% | -6.5% |
| Q4 25 | 3.8% | 3.0% | ||
| Q3 25 | 3.8% | 3.0% | ||
| Q2 25 | 4.3% | 2.3% | ||
| Q1 25 | 3.8% | 3.3% | ||
| Q4 24 | 4.0% | 3.1% | ||
| Q3 24 | 3.7% | 3.4% | ||
| Q2 24 | 4.1% | 2.3% | ||
| Q1 24 | 4.4% | 3.2% |
| Q4 25 | 1.07× | 2.41× | ||
| Q3 25 | 0.84× | 0.85× | ||
| Q2 25 | 1.42× | 0.80× | ||
| Q1 25 | 1.34× | -0.49× | ||
| Q4 24 | 0.98× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.67× | — | ||
| Q1 24 | 1.65× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTAS
| Uniform Rental And Facility Services Segment | $2.2B | 77% |
| First Aid And Safety Services Segment | $342.2M | 12% |
| Fire Protection Services | $222.5M | 8% |
| Uniform Direct Sales | $79.8M | 3% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
